Revenio Group Oyj

Revenio Group Corporation's Board of Directors has decided to issue shares in a directed share issue without payment, based on authorization from the Annual General Meeting on April 4, 2024. The shares will be given to key persons of the subsidiary Icare World Australia Pty Ltd. (formerly Oculo) as part of a long-term incentive and commitment program. This program, covering the years 2021-2023, aims to align the interests of shareholders and participants, support the company's strategy, and enhance long-term value and performance. A maximum of AUD 1,660,000 worth of shares was allocated, calculated at the trading-weighted average price on April 27, 2021. A total of 833 treasury shares will be transferred, leaving the company with 84,309 treasury shares. For more information, contact CFO Robin Pulkkinen. Revenio Group provides eye care diagnostic solutions and reported net sales of EUR 96.6 million and an operating profit of EUR 26.3 million in 2023. The company is listed on Nasdaq Helsinki with the trading code REG1V.

Revenio Group Corporation has issued an initial notification about a share-based incentive received by Bill Östman, a member of the board. The transaction involved 719 shares at a unit price of 0 EUR. Revenio Group is a global provider of eye care diagnostic solutions and is listed on Nasdaq Helsinki. In 2023, the company reported net sales of EUR 96.6 million and an operating profit of EUR 26.3 million.

Revenio Group Corporation has released a stock exchange notification concerning a share-based incentive received by Riad Sherif, a board member. The transaction took place outside a trading venue on May 7, 2024, and involved 457 shares at a unit price of 0 EUR. The notification is the initial one, with a reference number of 61954/4/4. Revenio Group, a global provider of eye care diagnostic solutions, recorded a net sales of EUR 96.6 million and an operating profit of EUR 26.3 million in 2023. The company is listed on Nasdaq Helsinki under the trading code REG1V.

Revenio Group Corporation has announced that Pekka Tammela, a member of the board, has received a share-based incentive. The transaction, which occurred outside a trading venue, involved 653 shares at a unit price of 0 EUR. The announcement was made in an initial notification, with a reference number of 61939/4/4. Further information can be obtained from CFO Robin Pulkkinen. Revenio Group Corporation is a provider of eye care diagnostic solutions and is listed on Nasdaq Helsinki. In 2023, the company's net sales were EUR 96.6 million, with an operating profit of EUR 26.3 million.

Revenio Group Corporation has issued an initial notification that Ann-Christine Sundell, a member of the board, has received a share-based incentive. The transaction, which occurred outside a trading venue, involved 457 shares at a unit price of 0 EUR. The company, a global provider of eye care diagnostic solutions, reported net sales of EUR 96.6 million and an operating profit of EUR 26.3 million in 2023. Revenio Group Corporation is listed on Nasdaq Helsinki under the trading code REG1V.

Revenio Group Corporation has transferred 3,200 treasury shares to its Board of Directors as part of their annual remuneration. This decision, made during the AGM on April 4, 2024, allows for around 40% of the Board's annual remuneration to be paid in company shares, with the remaining 60% being a monetary payment from which tax will be deducted. The share payment is valued using the weighted average value of the share on the day after the release of the Q1 2024 Interim Report. Following this transfer, Revenio now holds 85,142 of its treasury shares. The company's CFO, Robin Pulkkinen, is available for further information.

Revenio Group Corporation has announced that Arne Boye Nielsen, a member of the board, has received a share-based incentive. The transaction, which took place outside a trading venue, involved 914 shares at a unit price of 0 EUR. This is an initial notification, with the reference number 61945/4/4. The company is a global provider of eye care diagnostic solutions, with net sales in 2023 totaling EUR 96.6 million and an operating profit of EUR 26.3 million.